Press Releases

See our press releases below:

08/19/2010: Acceleron Pharma Receives FDA Orphan Designation for ACE-031 for the Treatment of Duchenne Muscular Dystrophy

08/04/2010: Acceleron Pharma Receives FDA Fast Track Designation for ACE-031 for the Treatment of Duchenne Muscular Dystrophy

05/05/2010: Acceleron Pharma Initiates Phase 2 Clinical Trial with ACE-031 in Patients with Duchenne Muscular Dystrophy

03/23/2010: Acceleron and Collaborators Publish Two Papers on ACE-041, a Novel Angiogenesis Inhibitor

03/10/2010: Acceleron Recognized by The Wall Street Journal as One of the Top 50 Venture-Backed Companies in the United States

03/01/2010: Acceleron to Present at the Cowen and Company 30th Annual Health Care Conference

01/14/2010: Acceleron Pharma Announces Addition of Two Novel Programs to Development Pipeline at the 28th Annual JP Morgan Healthcare Conference

01/07/2010: Acceleron Pharma to Present at the 28th Annual J.P. Morgan Healthcare Conference

12/22/2009: Acceleron Pharma Expands Management Team with Two New Appointments

12/08/2009: Acceleron Pharma Presents Findings of ACE-536, a Novel Red Blood Cell-Forming Agent, at the 51st Annual Meeting of the American Society of Hematology

12/03/2009: Alkermes Licenses Technology Platform for Long-Acting Fusion Proteins from Acceleron Pharma

12/01/2009: Acceleron Pharma to Present Data on ACE-011 and ACE-536 at the 51st Annual Meeting of the American Society of Hematology

11/04/2009: Acceleron Pharma Initiates First-in-Human Study of ACE-041, a Novel Angiogenesis Inhibitor, in Patients with Advanced Cancer

09/15/2009: Acceleron to Present at the UBS Global Life Sciences Conference

09/10/2009: Acceleron Pharma’s ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial

09/09/2009: Acceleron to Participate at the Morgan Stanley 2009 Global Healthcare Unplugged Conference

09/02/2009: Acceleron Pharma's ACE-031 Increases Lean Body Mass in Phase 1 Single Dose Clinical Trial

07/30/2009: Acceleron to Present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference

07/28/2009: Acceleron and Celgene Initiate Phase 2 Study of ACE-011 to Treat Chemotherapy-Induced Anemia

06/10/2009: Acceleron to Present ACE-031 Preclinical Study Results as Treatment for Loss of Muscle Mass and Function

06/08/2009: Acceleron Pharma to Present at Two Upcoming Investor Conferences

05/01/2009: Acceleron Announces Expansion of Cambridge Facilities by Additional 25% During Formal Unveiling of New Corporate Headquarters & Manufacturing Facility

05/01/2009: Acceleron Selected as One of Boston Business Journal’s 2009 Best Places to Work

04/14/2009: Acceleron Pharma Presents Preclinical Study Results for ACE-041 at the AACR 100th Annual Meeting 2009

03/26/2009: Acceleron to Present at the BioCentury Future Leaders in the Biotech Industry Conference

03/12/2009: Acceleron to Present at the Cowen and Company 29th Annual Health Care Conference

01/13/2009: Acceleron Introduces Breakthrough Program for Treatment of Anemia at the 27th Annual JP Morgan Healthcare Conference

01/06/2009: Acceleron to Present at the 27th Annual JP Morgan Healthcare Conference

12/18/2008: ACE-011 Phase 1 Results Published in the Journal of Bone and Mineral Research

12/03/2008: Celgene Corporation and Acceleron Pharma to Present ACE-011 Data at the 50th Annual Meeting of the American Society of Hematology

11/03/2008: Acceleron to Present at the Oppenheimer 19th Annual Health Care Conference

10/24/2008: Acceleron to Present at the 7th Annual Biotechnology Industry Organization Investor Forum

10/20/2008: Acceleron Initiates Phase 1 Clinical Trial for ACE-031 to Treat Diseases Involving Muscle Loss

10/16/2008: Celgene Corporation and Acceleron Pharma Initiate Phase 2 Study of ACE-011

09/30/2008: Acceleron to Present at Third Annual JMP Securities Healthcare Focus Conference

09/22/2008: Acceleron Pharma Acknowledged for Positive Impact on Economic Development in Massachusetts

09/19/2008: Acceleron to Present at the UBS Global Life Sciences Conference

06/19/2008: Acceleron to Present at the Jefferies 2nd Annual Healthcare Conference

06/16/2008: Acceleron Doubles Laboratory and Manufacturing Space and Increases Headcount by 40%

06/04/2008: Acceleron to Present at the Needham & Company 7th Annual Biotechnology and Medical Technology Conference

05/13/2008: Acceleron to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference

05/07/2008: ACE-011 Preclinical Data Published in the Proceedings of the National Academy of Sciences

03/24/2008: Acceleron Pharma and Celgene Corporation Receive Hart-Scott-Rodino Clearance for ACE-011 Collaboration

03/10/2008: Acceleron to Present at the Cowen and Company 28th Annual Health Care Conference

02/20/2008: Acceleron Pharma Announces Global Collaboration with Celgene Corporation on ACE-011 Program for Cancer-Related Bone Loss

01/23/2008: Acceleron Pharma Receives Grant for ACE-011 from the Multiple Myeloma Research Foundation

11/20/2007: Acceleron Pharma to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference

11/01/2007: Acceleron Pharma to Present at the Massachusetts Biotechnology Council’s 9th Annual MASS Opportunities Investment Conference

10/31/2007: Acceleron Pharma to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference

10/30/2007: Acceleron Pharma Completes $31M Series C Financing

10/18/2007: Acceleron Pharma’s ACE-031 Increases Muscle Mass In a Preclinical Model of Glucocorticoid-induced Muscle Loss

10/05/2007: Acceleron Pharma Website Awarded “Pharmaceutical Industry Standard of Excellence” by the Web Marketing Association

10/02/2007: Acceleron Pharma to Present at the Natixis Bleichroeder Hidden Gems Conference

09/24/2007: Acceleron Pharma Appoints Niels Borgstein, M.D. as Vice President, Medical Research

09/20/2007: Acceleron Pharma to Present at the UBS 2007 Global Life Sciences Conference

09/20/2007: Acceleron Pharma's ACE-011 Increases Bone Mineral Density and Bone Strength in Preclinical Studies in Non-Human Primates

09/18/2007: Acceleron Pharma Appoints John L. Knopf, Ph.D., as Chief Executive Officer

09/18/2007: Acceleron Pharma Presents Positive Phase 1 Results Demonstrating ACE-011 Increases Markers of Bone Formation

08/06/2007: Acceleron Pharma to Present ACE-011 Bone Growth Data at the ASBMR 29th Annual Meeting

07/31/2007: Acceleron Pharma to Present at the 27th Annual Canaccord Adams Global Growth Conference

06/26/2007: ACE-011 Improves Multiple Myeloma Bone Disease in a Preclinical Model

05/14/2007: Acceleron Pharma’s ACE-031 Increases Muscle Mass and Strength in Preclinical Studies

04/24/2007: Acceleron Pharma Appoints James Desiderio, Ph.D. as Vice President, Program Management

03/29/2007: Acceleron Pharma Appoints Robert Steininger as Senior Vice President, Manufacturing

03/07/2007: Acceleron Pharma to Present at the Cowen 27th Annual Health Care Conference

11/03/2006: Acceleron Pharma to Present at the Rodman & Renshaw 8th Annual Healthcare Conference

10/30/2006: Acceleron Pharma to Present at the MBC's MASS Opportunities Conference

09/18/2006: Acceleron Pharma Presents ACE-011 Preclinical Data Demonstrating Both Anabolic and Anti-Resorptive Properties

09/12/2006: Acceleron Pharma to Present ACE-011 Preclinical Data at the Annual Meeting of the American Society for Bone and Mineral Research

08/02/2006: Acceleron Pharma Closes $30M Series B Financing

06/21/2006: Acceleron Initiates Phase 1 Clinical Trial of ACE-011, a Novel Treatment for Bone Loss

05/16/2006: Acceleron Pharma Appoints Matthew L. Sherman, M.D. as Chief Medical Officer

06/14/2004: Acceleron Pharma Appoints Glenn Batchelder as CEO and Adds Richard F. Pops to Board of Directors

02/13/2004: Acceleron Pharma, Developing Drugs to Treat Musculoskeletal and Metabolic Disorders, Secures $25 Million in Series A Funding

BACK TO TOP